Company research / CHRS
Coherus Oncology, Inc. (CHRS)
- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
Partial revenue. In this company's filings, net income for the year ended 2025-12-31 is larger than reported revenue. The revenue it tags covers only part of its income (banks and REITs often tag only fee income this way, leaving out interest or rent), so it is not the company's whole top line. Margins on it are not computed, and it is left out of revenue rankings.
Key ratios (year ended 2025-12-31)
275.4%
Return on year-end equity
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.